The 23rd World Congress of Dermatology (WCD 2015) was held in Vancouver, Canada this week (8-13 June). Held every four years, the World Congress of Dermatology is the world’s oldest and continuous international dermatology meeting. The first Congress in 1889 pre-dated the modern Olympics by seven years.
This seemed a good time to look at some of the new developments that have happened in the global fight against skin disease.
MoleScope skin cancer app developed for smartphones in Vancouver
A new smartphone app for monitoring skin cancer made its debut at WCD 2015. Dr Maryam Sadeghi, director of the Digital Health Hub, designed the MoleScope app and device during her PhD research at Simon Fraser University.
The app works by attaching a mini-microscope to a smartphone camera, which takes images of skin moles and uploads them to a cloud-based analytical platform, where doctors can view it in closer detail.
Two versions of the MoleScope are expected to retail at $149.00, and a professional model will cost $200.00. The app currently only runs on iOS, with an Android version in the works.
Oculus Innovative Sciences has received FDA clearance for a new Atopic Dermatitis Dermatology product. Oculus is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The U.S. Food and Drug Administration (FDA) has cleared the company’s Alevicyn SG Antipruritic Spray Gel with both prescription and over-the-counter indications.
In this use, it is intended to relieve the burning and itching associated with many common types of skin irritation, lacerations, abrasions, and minor burns and is also indicated for the management of irritation and pain from minor burns, including sunburn.
Symptoms of atopic dermatitis are characterised by itchy skin, which can lead to rash, redness, swelling, crusting and scaling. The disease affects up to 20% of infants and young children, who continue to have symptoms as adults with significant impact on their quality of life. The exact cause is unknown, but genetics are considered a key factor.
Oculus will launch Alevicyn July 2015 in the U.S.
The announcement by Oculus comes ahead of a new global survey by GfK Disease Atlas, a real-world evidence programme linking doctor- and patient-reported treatment data. According to the survey:
- Over four out of 10 doctors and six out of 10 patients are not satisfied with the level of control achieved for moderate to severe atopic dermatitis adult patients treated with high potency topical steroids.
- Ninety One (91) per cent of moderate to severe atopic dermatitis adults receiving high potency topical steroids are expected to repeat this same treatment.
New Data Shows LEO Pharma A/S Investigational Psoriasis Treatment, Enstilar®, Provides Rapid Itch Relief for Psoriasis Patients
The clinical trial data that the company presented at the 23rd World Congress of Dermatology shows aerosol foam Enstilar® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g), the company’s dual-action investigational aerosol foam for the treatment of psoriasis vulgaris, provided rapid itch relief and improvements in itch-related sleep loss for patients suffering from psoriasis.
Between 70% and 90% of people with psoriasis suffer from itch, which can cause patients to experience additional stress or embarrassment. Moreover, psoriasis patients suffering from itch experience sweating, feel a sensation of heat or pain in the affected area and have difficulty falling asleep or are often awakened by the itching.
In December 2014, LEO Pharma submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Enstilar® and Marketing Authorisation Applications were submitted to 30 Regulatory Agencies in Europe in March 2015.
Christie Brinkley Authentic Skincare Line Receives The Skin Cancer Foundation’s Daily Use Seal Of Recommendation
This month, breakthrough anti-aging skincare line Christie Brinkley Authentic Skincare received the prestigious Daily Use Seal of Recommendation (the “Seal”) from The Skin Cancer Foundation, the only international organisation solely devoted to skin cancer prevention, early detection and prompt treatment. The Seal was awarded to the Recapture 360 + IR Defense Anti-Aging Day Treatment and the Recapture Day + IR Defense Anti-Aging Day Treatment. In addition to offering broad spectrum SPF 30 protection from UVA/UVB rays, these products offer infrared ray defence.
New drug can clear all psoriasis symptoms, it is claimed*
A new psoriasis drug has resulted in 40% of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90% showing improvement.
The research tested 2,500 people with psoriasis. Half were given a new drug – ixekizumab – either once every two or four weeks. The other half were given a placebo or a widely used drug for psoriasis called etanercept.
Chris Griffiths, Foundation Professor of Dermatology in Manchester University’s Faculty of Medical and Human Sciences and Salford Royal NHS Foundation Trust, led the research. He said:
The visible effects of psoriasis can have a major and life-ruining impact on people’s confidence and self-esteem.
What we saw in this trial was not just the physical aspects of the disease clearing up, but people on the new drug also reporting a marked improvement in their quality of life as they felt more confident and suffered less from itching – far more than in the other two groups.
New drugs are fast showing us that a realistic goal for all patients should be attaining clear skin and this trial very much sets us on that path.
What do you think of these latest developments? If you are a skin disease sufferer how do you think any of these developments might help you. Share your story or leave a comment below.
*Manchester University. “New drug can clear all psoriasis symptoms.” ScienceDaily. ScienceDaily, 10 June 2015. <www.sciencedaily.com/releases/2015/06/150610131558.htm>.